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PIN9
BUDGET IMPACT ANALYSIS OF INTRODUCING ROUTINE
VACCINATION WITH A QUADRIVALENT HPV-VACCINE
IN NORWAY
Kristensen FKO, Sverre JM, Nyhus K
PharmEcon, Asker, Akershus, Norway
OBJECTIVES: To model the likely impact of introducing routine
vaccination with a quadrivalent vaccine against HPV types 6, 11,
16 and 18 for 12 year old girls in Norway on relevant stakehold-
ers’ budgets over each of the ﬁrst 100 years. METHODS: An
excel-based budget impact model was developed, based on the
results of a mathematical model of the public health impact of
different immunization strategies using the quadrivalent HPV
vaccine. Natural disease history parameters were based upon
international data. Rates of HPV infection, mortality, cervical
cancer screening, treatment practice patterns and costs were
based upon Norwegian-speciﬁc data. Both routine vaccination of
12 year old girls and the additional effect of including a 5 year
catch-up vaccination program of females are modelled. The
model evaluates both the direct costs related to the vaccination
program, and cost savings due to reduced incidences of HPV-
related disease; cervical intraepithelial neoplasia (CIN), invasive
cancer and genital warts. The consequence for each stakeholder’s
budget is described: The Norwegian Institute of Public Health
(NIPH), the Norwegian Labour and Welfare Administration,
the four Regional Health Authorities, patients and employers.
RESULTS: The results are presented graphically and in tabular
form, for the various stakeholders and over time. Direct costs for
vaccination for the public payer are considerable, but are some-
what offset by savings for other stakeholders. The effect of the
vaccine on HPV 6 and 11 infections provides both earlier cost
offsets and increases them substantially. For the ﬁrst 35 years the
majority of discounted costs avoided are due to the prevention of
HPV 6 and 11 infections. CONCLUSIONS: This analysis dem-
onstrates the beneﬁt of analyzing budgetary consequences per
stakeholder, over time and for virus types covered. It is important
to model budget consequences not only from the public payer’s
perspective but also from a societal one.
PIN10
THE ECONOMIC IMPACT OF LOWER HIV
PREVALENCE ESTIMATES
Ho J, Becker RV
Dymaxium Inc,Toronto, ON, Canada
OBJECTIVES: The “AIDS epidemic update” (2007) published
by the United Nations (UN) and World Health Organization
(WHO) recently reported lowered estimates for the number of
person infected with HIV worldwide. This study examines the
economic impact of these revised ﬁgures upon the costs associ-
ated with treating patients with antiretroviral (ARV) drugs or
opportunistic infection (OI) prophylaxis. METHODS: The
annual change in the number of persons infected with HIV in
eight regions worldwide was calculated for 2006 and 2007
from the UN report. Average treatment rates were used to deter-
mine the number of patients treated with ARV or OI prophy-
laxis. The difference in the cost for treating these patients was
estimated by multiplying the average cost of treatment by the
number of patients treated. For ARVs, the average cost estimate
for 2006 (USD) included ﬁrst- and second-line drugs, lab costs,
inpatient and outpatient costs and counseling. For OI prophy-
laxis, only drug and counseling costs were included. Low- and
high-cost ranges were used to estimate drug costs. Only coun-
seling, inpatient and outpatient costs varied by region. Sensitiv-
ity analysis was conducted on key inputs. RESULTS: The
impact of 6.26 million fewer patients from 2007 to 2006 is
estimated to be a total cost saving of USD$1.08 billion, or a
16.4% reduction in treatment costs. The new estimates yield a
$952 million and a $129 million saving in annual ART and OI
prophylaxis costs, respectively, compared to the 2006 estimates.
Although the Sub-Saharan Africa region has the largest HIV
prevalence, the revised estimates had the greatest impact on the
total costs in South and South-East Asia, with a 48.7% reduc-
tion. CONCLUSIONS: The lower prevalence estimates provide
a signiﬁcant budget savings which varies greatly among regions.
Upon further analysis, using more detailed prevalence and cost
data, the savings may show even greater differences among
countries within the same region.
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COST-EFFECTIVENESS OF QUADRIVALENT HPV
VACCINATION IN FINLAND
Väänänen JJP1, Herse F1, Korkeamäki J2, Parvinen PMT1, Remy O3
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OBJECTIVES: To determine costs caused by human papilloma-
virus (HPV) and to evaluate the cost-effectiveness of vaccinating
12 year old females with a quadrivalent HPV vaccine in Finland.
METHODS: A comprehensive analysis, based on Finnish
national health care, social insurance and cancer registries,
allowed to evaluate the costs associated with cervical cancers,
cervical lesions and genital warts diagnosed between 2001 and
2005 (health care costs, sick-leave compensations, disability
pensions, and loss of productivity). An incidence-based model
working in discrete time steps was developed to evaluate the
effects of HPV vaccine. The model utilised Monte Carlo simula-
tion to produce the outputs. Age-speciﬁc cervical cancer inci-
dence rates were derived from population-based cancer registries.
The model followed four cohorts of 12 year old females through
their lives and the vaccine was assumed to be 100% effective
against HPV types 6, 11, 16, 18. The analysis was performed
from health care payer and societal perspectives. Sensitivity
analyses were carried out to explore the effects of discount rates.
RESULTS: Screening and management of HPV related diseases
cost annually €50 M in Finland. Treatment of genital warts,
cervical dysplasia and cancer costs €37 M. Solely pap screening
costs €13 M. Vaccination of 12 year old females against HPV
types 6, 11, 16 and 18 would cost €6,957 per additional QALY
gained (no discounting) and €11,122/QALY (3.5% discounting
for money and 1.5% for health beneﬁts). CONCLUSIONS:
Currently HPV causes signiﬁcant health care costs for Finland.
As €50,000/QALY is generally considered to be the threshold of
cost-effective treatment in the developed countries, vaccination
of 12 years old girls against 6, 11, 16, 18 HPV types would be
an effective and economically proﬁtable method to reduce the
burden of the HPV related diseases.
PIN12
COST-EFFECTIVENESS OF CERVARIX™,A PROPHYLACTIC
CERVICAL CANCERVACCINE, IN SPAIN
Gauthier A1, Moore L1, Martín-Escudero V2, Peterson C1, Pérez I2,
de Sanjosé S3
1i3 Innovus, Uxbridge, UK, 2GlaxoSmithKline, Madrid, Spain,
3ICO-CIBERESP, Barcelona, Spain
OBJECTIVES: Vaccination against human papillomavirus
(HPV) has been recommended in Spain for girls aged 11–14 years
old. Our objective was to estimate the cost-effectiveness of the
bivalent HPV-16/18 AS04 adjuvant vaccine, Cervarix™ (Glaxo-
SmithKline), in the current Spanish setting with cervical cancer
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screening. METHODS: A Markov model based on the natural
history of HPV and cervical cancer (CC) was developed to simu-
late transitions between health states (normal, HPV infection,
Cervical Intraepithelial Neoplasia (CIN) stages 1–3, CC stages
1–4, and death) in the presence of the current opportunistic
screening practices in Spain. The model was calibrated to Spanish
epidemiological endpoints: age-speciﬁc HPV and CIN preva-
lence, and age-speciﬁc CC incidence and mortality. Spanish data
was used to inform observed costs, screening and treatment
practices in Spain. Published efﬁcacy rates were used for the
HPV-16/18 vaccine including protection against non-vaccine
oncogenic HPV types (such as efﬁcacy against HPV-31 and -45).
RESULTS: Assuming the screening practices remain unchanged,
vaccinating all 12-year old girls would result in 79.1% and
79.5% decreases in the number of CC cases and deaths, respec-
tively. Vaccination would also produce substantial reductions in
the number of repeat screening tests due to abnormal cytology
and treatments for cervical dysplasia, which would partially
offset the cost of the vaccine. The introduction of Cervarix™ in
the current screening setting was predicted to result in an incre-
mental cost effectiveness ratio (ICER) of €31,749 per quality
adjusted life year (QALY) gained, when discounting at 3% for
costs and outcomes. Discounting at 4% for costs and 1.5% for
outcomes resulted in an ICER of €14,707 per QALY gained.
CONCLUSIONS: Universal vaccination with Cervarix™ for
12-year old girls within the current screening setting in Spain, is
predicted to be a cost-effective method of reducing precancerous
cervical lesions, cervical cancer incidence and mortality.
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ECONOMIC ANALYSIS OF MICAFUNGINVERSUS LIPOSOMAL
AMPHOTERICIN B FORTREATMENT OF CANDIDAEMIA AND
INVASIVE CANDIDIASIS IN ITALY
Viale P1, Sidhu M2, van Engen A3, Schoeman O3
1Policlinico Universitario di Udine, Udine, Italy, 2Astellas Pharma
Europe Ltd, Staines, UK, 3Quintiles Consulting, Hoofddorp,The
Netherlands
OBJECTIVES: To investigate the economic impact of introduc-
ing micafungin (MICA) for the treatment of systemic candida
infections (SCIs) (including invasive candidiasis and can-
didaemia) in Italy, a health economic analysis was performed
comparing MICA with liposomal amphotericin B (L-AMB).
METHODS: The model was based on data from a phase III,
randomised, double-blind trial comparing MICA with L-AMB.
The model entailed a period of 14–20 weeks from initiation of
treatment and was analysed from an Italian hospital perspective.
The analysis included hospitalisation and primary medication
costs. Unit costs of these resources were taken from Italian
costing sources. As the price for MICA was not available at the
time of analysis, the price per recommended daily dose (RDD) of
MICA (100 mg) was assumed to be equal to the price per RDD
of caspofungin (50 mg). The model endpoint was deﬁned as the
percentage of patients predicted to achieve complete or partial
clinical and mycological response after initial treatment, and be
alive after the 12-week follow-up period. The model was analy-
sed using cohort and second-order Monte Carlo (MC) simula-
tion. RESULTS: The analysis of this model shows that with
MICA 52.9% of patients were predicted to have treatment
success and survive 12 weeks after end of treatment compared
with 49.1% for L-AMB. MICA was predicted to be less expen-
sive than L-AMB costing €28,668 and €40,760 per patient,
respectively. Because of lower simulated costs and the higher
effectiveness of MICA (cost-effectiveness [C/E] ratio = €54,215)
compared with L-AMB (C/E ratio = €83,035), MICA dominates
L-AMB. The results of the MC simulation and sensitivity analy-
ses showed that MICA remained the most cost-effective option.
CONCLUSIONS: The lower costs and higher effectiveness pre-
dicted for MICA versus L-AMB in this analysis indicate that in
Italy, MICA is more cost-effective for the treatment of SCIs when
compared with L-AMB.
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USING A DECISION SIMULATION MODELTO EVALUATE
THE COST-EFFECTIVENESS OFTHETREATMENT OF
NUCLEOSIDE-NAÏVE HBE-ANTIGEN NEGATIVE CHB
PATIENTS IN ITALY WITH ENTECAVIR ANDTENOFOVIR
Zammit DC1,Yuan Y2, Intorcia M3, Hay JW4
1Bristol-Myers Squibb, Braine l-A’lleud, Belgium, 2Bristol-Myers Squibb,
Princeton, NJ, USA, 3Bristol-Myers Squibb, Rome, Italy, 4University of
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OBJECTIVES: To simulate the treatment of nucleoside-naïve
HBe antigen negative CHB patients with entecavir or tenofovir
in the absence of head-to-head data for cost effectiveness com-
parison. METHODS: A hypothetical cohort of 1000 received
treatment with entecavir 0.5 mg or tenofovir 300 mg daily for
48 weeks. A patient level simulation model was developed to
estimate HBV DNA distributions, assuming a parametric dis-
tribution for baseline viral load (VL) and mean drop at 48
weeks, based on summary statistics from two RCTs; BMS
AI-463027 (entecavir) and GS 174-0102 (tenofovir). Efﬁcacy
outcomes were calibrated to the end points from both trials.
Liver complications over 10 years were projected using relative
risks for CHB progression for ﬁve HBV DNA categories
(R.E.V.E.A.L.-HBV epidemiology study). The Italian payer per-
spective was applied. Direct medical costs: drug acquisition,
associated physician visits, clinical monitoring, liver event man-
agement. All model inputs estimated from published data. Dis-
count rate: 3%. RESULTS: A simulation based on baseline VL
from the tenofovir trial, entecavir was superior to tenofovir in
mean serum HBV DNA reduction at 48 weeks, with drops of
5.0 vs 4.57 log10 copies/mL, leading to 97.8% and 91.1% of
patients reaching undetectable VL respectively. For 1000
patients, the projected number of HCC and DC events within
10 years were 36 and 5, and 71 and 13, for entecavir and
tenofovir respectively. Entecavir therapy was dominant, demon-
strating €934 saving in discounted lifetime medical costs and
QALY gain of 0.62 per patient. These estimates dropped to
€773 and 0.58 QALY respectively in a sensitivity analysis to
using the mean entecavir baseline VL, resulting in 90.1% and
82% of entecavir and tenofovir patients reaching undetectable
VL at 48 weeks respectively. CONCLUSIONS: In absence of
head-to-head data between the two agents, entecavir was pro-
jected to be a clinically and economically attractive alternative
to tenofovir in this patient population.
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COST-EFFECTIVENESS OF PALIVIZUMAB INTHE
PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV:
RESULTS OF A DECISION MODEL WITH LOCAL DATA
García-Altés A1, Paladio N2, Pons J2,Tebé C2
1Fundación Instituto de Investigación en Servicios de Salud, Barcelona,
Spain, 2Catalan Agency for Health Technology Assessment and
Research, Barcelona, Spain
OBJECTIVES: Viral bronchiolitis is the most frequent cause of
infection of the lower respiratory tract among children younger
than 12 months old, with frequent hospitalizations and rare
deaths. Palivizumab, a high cost drug, is approved for VSR
prophylaxis. Our objective was to assess the cost-effectiveness
of palivizumab in the prophylaxis of RSV bronchiolitis in high
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